West Pharmaceutical ups FY25 adjusted EPS view to $6.15-$6.35 from $6.00-$6.20

Consensus $6.19. Raises FY25 revenue view to $2.95B-$2.98B from $2.88B-$2.91B, consensus $2.9B. The company said, “As a result of favorable foreign currency movements, the Company is increasing its full year 2025 net sales guidance range to $2.945 billion to $2.975 billion, up from previous guidance of $2.875 billion to $2.905 billion. Net sales guidance includes an estimated full-year 2025 headwind of approximately $5.0 million based on current foreign currency exchange rates, compared to previous guidance of a headwind of approximately $75 million. Full-year 2025 capital spending guidance is unchanged and is expected to be $275 million.”